Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-09-28. The firm is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The firm has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
Follow-Up Questions
ZAILF の株価パフォーマンスは？
ZAILF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Zai Lab Ltd の主な事業テーマや業界は？
Zai Lab Ltd は Biotechnology 業界、セクターは Health Care に属しています。
